Pasireotide Diaspartate (BioDeep_00000844319)
代谢物信息卡片
Pasireotide Diaspartate
化学式: C66H80N12O17 (1312.5764110000002)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN.C(C(C(=O)O)N)C(=O)O.C(C(C(=O)O)N)C(=O)O
InChI: 2*2-/m100/s1
描述信息
D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones
同义名列表
1 个代谢物同义名
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Libuse Tauchmanova, Astrid Breitschaft, Geoffrey Holder, Kevin Tianxiang Han, Somesh Choudhury, Christelle Darstein, Michaela Paul, Eric Drutinus, Germo Gericke, Herbert A Schmid, Alberto M Pedroncelli. Combination of pasireotide and octreotide: effects on GH and IGF-I secretion and glucose metabolism in healthy volunteers.
Endocrine.
2022 Feb; 75(2):537-548. doi:
10.1007/s12020-021-02908-6. [PMID: 34741720] - Susan L Samson, Feng Gu, Ulla Feldt-Rasmussen, Shaoling Zhang, Yerong Yu, Przemysław Witek, Pramila Kalra, Alberto M Pedroncelli, Philippe Pultar, Nadine Jabbour, Michaela Paul, Marek Bolanowski. Managing pasireotide-associated hyperglycemia: a randomized, open-label, Phase IV study.
Pituitary.
2021 Dec; 24(6):887-903. doi:
10.1007/s11102-021-01161-4. [PMID: 34275099] - Kensaku Fukunaga, Hitomi Imachi, Seisuke Sato, Toshihiro Kobayashi, Yuki Yoshioka, Takanobu Saheki, Natsuki Ban, Kurumi Urushihara, Jingya Lyu, Tao Dong, Ryou Ishikawa, Kyuichi Kadota, Reiji Haba, Naoko Inoshita, Koji Murao. Successful Therapy Using Pasireotide Long-acting Release for Cushing's Disease Merged with Biochemical Acromegaly.
Internal medicine (Tokyo, Japan).
2021 Apr; 60(7):1047-1053. doi:
10.2169/internalmedicine.4663-20. [PMID: 33162471] - Kazunori Kageyama, Rie Hagiwara, Kanako Niioka, Shinobu Takayasu, Makoto Daimon. Differential effects of β-arrestin1 and β-arrestin2 on somatostatin receptors in murine AtT-20 corticotroph tumor cells.
Endocrine journal.
2021 Feb; 68(2):163-170. doi:
10.1507/endocrj.ej20-0251. [PMID: 32963176] - Max Sauter, Philipp Uhl, Jürgen Burhenne, Walter E Haefeli. Application of triple quadrupole tandem mass spectrometry to the bioanalysis of collision-induced dissociation-resistant cyclic peptides - Ultra-sensitive quantification of the somatostatin-analog pasireotide utilizing UHPLC-MS/MS.
Journal of pharmaceutical and biomedical analysis.
2021 Feb; 194(?):113728. doi:
10.1016/j.jpba.2020.113728. [PMID: 33234413] - Rémi Samain, Alexia Brunel, Thibault Douché, Marjorie Fanjul, Stéphanie Cassant-Sourdy, Julia Rochotte, Jérôme Cros, Cindy Neuzillet, Jérôme Raffenne, Camille Duluc, Aurélie Perraud, Jérémy Nigri, Véronique Gigoux, Ivan Bieche, Matteo Ponzo, Gilles Carpentier, Ilaria Cascone, Richard Tomasini, Herbert A Schmid, Muriel Mathonnet, Rémy Nicolle, Marie-Pierre Bousquet, Yvan Martineau, Stéphane Pyronnet, Christine Jean, Corinne Bousquet. Pharmacologic Normalization of Pancreatic Cancer-Associated Fibroblast Secretome Impairs Prometastatic Cross-Talk With Macrophages.
Cellular and molecular gastroenterology and hepatology.
2021; 11(5):1405-1436. doi:
10.1016/j.jcmgh.2021.01.008. [PMID: 33482394] - A Lacroix, M D Bronstein, J Schopohl, T Delibasi, R Salvatori, Y Li, A Barkan, N Suzaki, L Tauchmanova, C-E Ortmann, S Ravichandran, S Petersenn, R Pivonello. Long-acting pasireotide improves clinical signs and quality of life in Cushing's disease: results from a phase III study.
Journal of endocrinological investigation.
2020 Nov; 43(11):1613-1622. doi:
10.1007/s40618-020-01246-0. [PMID: 32385851] - Marie C Hogan, Julie A Chamberlin, Lisa E Vaughan, Angela L Waits, Carly Banks, Kathleen Leistikow, Troy Oftsie, Chuck Madsen, Marie Edwards, James Glockner, Walter K Kremers, Peter C Harris, Nicholas F LaRusso, Vicente E Torres, Tatyana V Masyuk. Pansomatostatin Agonist Pasireotide Long-Acting Release for Patients with Autosomal Dominant Polycystic Kidney or Liver Disease with Severe Liver Involvement: A Randomized Clinical Trial.
Clinical journal of the American Society of Nephrology : CJASN.
2020 09; 15(9):1267-1278. doi:
10.2215/cjn.13661119. [PMID: 32843370] - John Newell-Price, Rosario Pivonello, Antoine Tabarin, Maria Fleseriu, Przemysław Witek, Mônica R Gadelha, Stephan Petersenn, Libuse Tauchmanova, Shoba Ravichandran, Pritam Gupta, André Lacroix, Beverly M K Biller. Use of late-night salivary cortisol to monitor response to medical treatment in Cushing's disease.
European journal of endocrinology.
2020 Feb; 182(2):207-217. doi:
10.1530/eje-19-0695. [PMID: 31804965] - Maria Fleseriu, Stephan Petersenn, Beverly M K Biller, Pinar Kadioglu, Christophe De Block, Guy T'Sjoen, Marie-Christine Vantyghem, Libuse Tauchmanova, Judi Wojna, Michael Roughton, André Lacroix, John Newell-Price. Long-term efficacy and safety of once-monthly pasireotide in Cushing's disease: A Phase III extension study.
Clinical endocrinology.
2019 12; 91(6):776-785. doi:
10.1111/cen.14081. [PMID: 31465533] - Rosario Pivonello, Giorgio Arnaldi, Carla Scaroni, Carla Giordano, Salvo Cannavò, Davide Iacuaniello, Laura Trementino, Marialuisa Zilio, Valentina Guarnotta, Adriana Albani, Alessia Cozzolino, Grazia Michetti, Marco Boscaro, Annamaria Colao. The medical treatment with pasireotide in Cushing's disease: an Italian multicentre experience based on 'real-world evidence'.
Endocrine.
2019 06; 64(3):657-672. doi:
10.1007/s12020-018-1818-7. [PMID: 30968338] - Richard A Feelders, John Newell-Price, Rosario Pivonello, Lynnette K Nieman, Leo J Hofland, Andre Lacroix. Advances in the medical treatment of Cushing's syndrome.
The lancet. Diabetes & endocrinology.
2019 04; 7(4):300-312. doi:
10.1016/s2213-8587(18)30155-4. [PMID: 30033041] - Hélène Lasolle, Alexandre Vasiljevic, Françoise Borson-Chazot, Gerald Raverot. Pasireotide: A potential therapeutic alternative for resistant prolactinoma.
Annales d'endocrinologie.
2019 Apr; 80(2):84-88. doi:
10.1016/j.ando.2018.07.013. [PMID: 30318256] - Mattia Barbot, Valentina Guarnotta, Marialuisa Zilio, Filippo Ceccato, Alessandro Ciresi, Andrea Daniele, Giuseppe Pizzolanti, Elena Campello, Anna Chiara Frigo, Carla Giordano, Carla Scaroni. Effects of pasireotide treatment on coagulative profile: a prospective study in patients with Cushing's disease.
Endocrine.
2018 10; 62(1):207-214. doi:
10.1007/s12020-018-1669-2. [PMID: 29980915] - Eleni Daniel, Miguel Debono, Sharon Caunt, Constantine Girio-Fragkoulakis, Stephen J Walters, Scott A Akker, Ashley B Grossman, Peter J Trainer, John Newell-Price. A prospective longitudinal study of Pasireotide in Nelson's syndrome.
Pituitary.
2018 Jun; 21(3):247-255. doi:
10.1007/s11102-017-0853-3. [PMID: 29313180] - Maya Lottati, David S Bruyette. Outcomes of the addition of pasireotide to traditional adrenal-directed treatment for dogs with pituitary-dependent hyperadrenocorticism secondary to macroadenoma: 9 cases (2013-2015).
Journal of the American Veterinary Medical Association.
2018 Jun; 252(11):1403-1408. doi:
10.2460/javma.252.11.1403. [PMID: 29772978] - J Tack, J Aberle, J Arts, M Laville, J-M Oppert, G Bender, S Bhoyrul, T McLaughlin, T Yoshikawa, A Vella, J Zhou, V Q Passos, P O'Connell, A P Van Beek. Safety and efficacy of pasireotide in dumping syndrome-results from a phase 2, multicentre study.
Alimentary pharmacology & therapeutics.
2018 06; 47(12):1661-1672. doi:
10.1111/apt.14664. [PMID: 29696671] - Maria Lorenzo Pisarello, Tatyana V Masyuk, Sergio A Gradilone, Anatoliy I Masyuk, Jingyi F Ding, Pui-Yuen Lee, Nicholas F LaRusso. Combination of a Histone Deacetylase 6 Inhibitor and a Somatostatin Receptor Agonist Synergistically Reduces Hepatorenal Cystogenesis in an Animal Model of Polycystic Liver Disease.
The American journal of pathology.
2018 04; 188(4):981-994. doi:
10.1016/j.ajpath.2017.12.016. [PMID: 29366679] - Anatoliy I Masyuk, Tatyana V Masyuk, Maria J Lorenzo Pisarello, Jingyi Francess Ding, Lorena Loarca, Bing Q Huang, Nicholas F LaRusso. Cholangiocyte autophagy contributes to hepatic cystogenesis in polycystic liver disease and represents a potential therapeutic target.
Hepatology (Baltimore, Md.).
2018 03; 67(3):1088-1108. doi:
10.1002/hep.29577. [PMID: 29023824] - André Lacroix, Feng Gu, Wilson Gallardo, Rosario Pivonello, Yerong Yu, Przemysław Witek, Marco Boscaro, Roberto Salvatori, Masanobu Yamada, Libuse Tauchmanova, Michael Roughton, Shoba Ravichandran, Stephan Petersenn, Beverly M K Biller, John Newell-Price. Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial.
The lancet. Diabetes & endocrinology.
2018 01; 6(1):17-26. doi:
10.1016/s2213-8587(17)30326-1. [PMID: 29032078] - Piero Ferolla, Maria Pia Brizzi, Tim Meyer, Wasat Mansoor, Julien Mazieres, Christine Do Cao, Hervé Léna, Alfredo Berruti, Vincenzo Damiano, Wieneke Buikhuisen, Henning Grønbæk, Catherine Lombard-Bohas, Christian Grohé, Vincenzo Minotti, Marcello Tiseo, Javier De Castro, Nicholas Reed, Gabriella Gislimberti, Neha Singh, Miona Stankovic, Kjell Öberg, Eric Baudin. Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial.
The Lancet. Oncology.
2017 12; 18(12):1652-1664. doi:
10.1016/s1470-2045(17)30681-2. [PMID: 29074099] - Tatyana V Masyuk, Anatoliy I Masyuk, Maria Lorenzo Pisarello, Brynn N Howard, Bing Q Huang, Pui-Yuen Lee, Xavier Fung, Eduard Sergienko, Robert J Ardecky, Thomas D Y Chung, Anthony B Pinkerton, Nicholas F LaRusso. TGR5 contributes to hepatic cystogenesis in rodents with polycystic liver diseases through cyclic adenosine monophosphate/Gαs signaling.
Hepatology (Baltimore, Md.).
2017 10; 66(4):1197-1218. doi:
10.1002/hep.29284. [PMID: 28543567] - M H Kulke, P Ruszniewski, E Van Cutsem, C Lombard-Bohas, J W Valle, W W De Herder, M Pavel, E Degtyarev, J C Brase, L Bubuteishvili-Pacaud, M Voi, R Salazar, I Borbath, N Fazio, D Smith, J Capdevila, R P Riechelmann, J C Yao. A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial.
Annals of oncology : official journal of the European Society for Medical Oncology.
2017 06; 28(6):1309-1315. doi:
10.1093/annonc/mdx078. [PMID: 28327907] - R Gostelow, C Scudder, S Keyte, Y Forcada, R C Fowkes, H A Schmid, D B Church, S J M Niessen. Pasireotide Long-Acting Release Treatment for Diabetic Cats with Underlying Hypersomatotropism.
Journal of veterinary internal medicine.
2017 Mar; 31(2):355-364. doi:
10.1111/jvim.14662. [PMID: 28145031] - Maria Fleseriu, Elisha Rusch, Eliza B Geer. Safety and tolerability of pasireotide long-acting release in acromegaly-results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) study.
Endocrine.
2017 Jan; 55(1):247-255. doi:
10.1007/s12020-016-1182-4. [PMID: 27896545] - Masanori Kugita, Kazuhiro Nishii, Tamio Yamaguchi, Atsushi Suzuki, Yukio Yuzawa, Shigeo Horie, Eiji Higashihara, Shizuko Nagao. Beneficial effect of combined treatment with octreotide and pasireotide in PCK rats, an orthologous model of human autosomal recessive polycystic kidney disease.
PloS one.
2017; 12(5):e0177934. doi:
10.1371/journal.pone.0177934. [PMID: 28542433] - Charles J Yeo. Invited Commentary: Pasireotide and the Prevention of Pancreatic Fistula After Pancreatectomy: 'The Continued Search for Harry Potter's Liquid Luck'.
Annals of surgery.
2017 01; 265(1):17-19. doi:
10.1097/sla.0000000000001975. [PMID: 27611616] - Susan L Samson. Management of Hyperglycemia in Patients With Acromegaly Treated With Pasireotide LAR.
Drugs.
2016 Sep; 76(13):1235-1243. doi:
10.1007/s40265-016-0615-y. [PMID: 27473537] - Herbert A Schmid, Thierry Brue, Annamaria Colao, Mônica R Gadelha, Ilan Shimon, Karen Kapur, Alberto M Pedroncelli, Maria Fleseriu. Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly.
Endocrine.
2016 Jul; 53(1):210-9. doi:
10.1007/s12020-016-0895-8. [PMID: 26906713] - S Cannavo, E Messina, A Albani, F Ferrau, V Barresi, S Priola, F Esposito, F Angileri. Clinical management of critically ill patients with Cushing's disease due to ACTH-secreting pituitary macroadenomas: effectiveness of presurgical treatment with pasireotide.
Endocrine.
2016 Jun; 52(3):481-7. doi:
10.1007/s12020-015-0601-2. [PMID: 25877016] - L Trementino, G Michetti, A Angeletti, G Marcelli, C Concettoni, C Cardinaletti, B Polenta, M Boscaro, G Arnaldi. A Single-Center 10-Year Experience with Pasireotide in Cushing's Disease: Patients' Characteristics and Outcome.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
2016 May; 48(5):290-8. doi:
10.1055/s-0042-101347. [PMID: 27127913] - Yunlin Fu, Yuan-Qing Xia, Jimmy Flarakos, Francis L S Tse, Jeffrey D Miller, Elliott B Jones, Wenkui Li. Differential Mobility Spectrometry Coupled with Multiple Ion Monitoring in Regulated LC-MS/MS Bioanalysis of a Therapeutic Cyclic Peptide in Human Plasma.
Analytical chemistry.
2016 Apr; 88(7):3655-61. doi:
10.1021/acs.analchem.5b04408. [PMID: 26937555] - Antonio Stigliano, Vincenzo Toscano. [Indications and future perspectives in the pharmacological treatment of hypercortisolism].
Recenti progressi in medicina.
2016 Mar; 107(3):143-8. doi:
10.1701/2182.23606. [PMID: 27030224] - Yunlin Fu, Wenkui Li, Jimmy Flarakos, Francis L S Tse. Quantitative analysis of pasireotide (SOM230), a cyclic peptide, in monkey plasma using liquid chromatography in combination with tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2016 Jan; 1008(?):242-249. doi:
10.1016/j.jchromb.2015.11.025. [PMID: 26680325] - Jarosław B Ćwikła, Lisa Bodei, Agnieszka Kolasinska-Ćwikła, Artur Sankowski, Irvin M Modlin, Mark Kidd. Circulating Transcript Analysis (NETest) in GEP-NETs Treated With Somatostatin Analogs Defines Therapy.
The Journal of clinical endocrinology and metabolism.
2015 Nov; 100(11):E1437-45. doi:
10.1210/jc.2015-2792. [PMID: 26348352] - Amit Mahipal, Dave Shibata, Erin Siegel, Gregory Springett, Khaldoun Almhanna, William Fulp, Irene Williams-Elson, Richard Kim. Phase I trial of combination of FOLFIRI and pasireotide, a somatostatin analogue, in advanced gastrointestinal malignancies.
Investigational new drugs.
2015 Oct; 33(5):1093-9. doi:
10.1007/s10637-015-0277-8. [PMID: 26275531] - Jochen Schopohl, Feng Gu, Robert Rubens, Luc Van Gaal, Jérôme Bertherat, Monica Ligueros-Saylan, Andrew Trovato, Gareth Hughes, Luiz R Salgado, Marco Boscaro, Rosario Pivonello. Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing's disease: results from an open-ended, open-label extension trial.
Pituitary.
2015 Oct; 18(5):604-12. doi:
10.1007/s11102-014-0618-1. [PMID: 25537481] - L Trementino, M Zilio, G Marcelli, G Michetti, M Barbot, F Ceccato, M Boscaro, C Scaroni, G Arnaldi. The role of an acute pasireotide suppression test in predicting response to treatment in patients with Cushing's disease: findings from a pilot study.
Endocrine.
2015 Sep; 50(1):154-61. doi:
10.1007/s12020-014-0499-0. [PMID: 25500791] - R A Dumbell, F Scherbarth, V Diedrich, H A Schmid, S Steinlechner, P Barrett. Somatostatin Agonist Pasireotide Promotes a Physiological State Resembling Short-Day Acclimation in the Photoperiodic Male Siberian Hamster (Phodopus sungorus).
Journal of neuroendocrinology.
2015 Jul; 27(7):588-99. doi:
10.1111/jne.12289. [PMID: 25950084] - C J Scudder, R Gostelow, Y Forcada, H A Schmid, D Church, S J M Niessen. Pasireotide for the Medical Management of Feline Hypersomatotropism.
Journal of veterinary internal medicine.
2015 Jul; 29(4):1074-80. doi:
10.1111/jvim.12608. [PMID: 25945588] - Laura Trementino, Marina Cardinaletti, Carolina Concettoni, Giorgia Marcelli, Marco Boscaro, Giorgio Arnaldi. Up-to 5-year efficacy of pasireotide in a patient with Cushing's disease and pre-existing diabetes: literature review and clinical practice considerations.
Pituitary.
2015 Jun; 18(3):359-65. doi:
10.1007/s11102-014-0582-9. [PMID: 24952218] - Laura Trementino, Marina Cardinaletti, Carolina Concettoni, Giorgia Marcelli, Barbara Polenta, Maurizio Spinello, Marco Boscaro, Giorgio Arnaldi. Salivary cortisol is a useful tool to assess the early response to pasireotide in patients with Cushing's disease.
Pituitary.
2015 Feb; 18(1):60-7. doi:
10.1007/s11102-014-0557-x. [PMID: 24482099] - Darryl Lau, Caleb Rutledge, Manish K Aghi. Cushing's disease: current medical therapies and molecular insights guiding future therapies.
Neurosurgical focus.
2015 Feb; 38(2):E11. doi:
10.3171/2014.10.focus14700. [PMID: 25639313] - Katharina Hopp, Cynthia J Hommerding, Xiaofang Wang, Hong Ye, Peter C Harris, Vicente E Torres. Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model.
Journal of the American Society of Nephrology : JASN.
2015 Jan; 26(1):39-47. doi:
10.1681/asn.2013121312. [PMID: 24994926] - Jessica MacKenzie Feder, Isabelle Bourdeau, Sophie Vallette, Hugues Beauregard, Louis-Georges Ste-Marie, André Lacroix. Pasireotide monotherapy in Cushing's disease: a single-centre experience with 5-year extension of phase III Trial.
Pituitary.
2014 Dec; 17(6):519-29. doi:
10.1007/s11102-013-0539-4. [PMID: 24287689] - Shingo Murasawa, Kazunori Kageyama, Aya Sugiyama, Noriko Ishigame, Kanako Niioka, Toshihiro Suda, Makoto Daimon. Inhibitory effects of SOM230 on adrenocorticotropic hormone production and corticotroph tumor cell proliferation in vitro and in vivo.
Molecular and cellular endocrinology.
2014 Aug; 394(1-2):37-46. doi:
10.1016/j.mce.2014.07.001. [PMID: 25011056] - M Boscaro, J Bertherat, J Findling, M Fleseriu, A B Atkinson, S Petersenn, J Schopohl, P Snyder, G Hughes, A Trovato, K Hu, M Maldonado, B M K Biller. Extended treatment of Cushing's disease with pasireotide: results from a 2-year, Phase II study.
Pituitary.
2014 Aug; 17(4):320-6. doi:
10.1007/s11102-013-0503-3. [PMID: 23943009] - Magdy Shenouda, Mario Maldonado, Yanfeng Wang, Emmanuel Bouillaud, Michelle Hudson, Dalal Nesheiwat, Ke Hu. An open-label dose-escalation study of once-daily and twice-daily pasireotide in healthy volunteers: safety, tolerability, and effects on glucose, insulin, and glucagon levels.
American journal of therapeutics.
2014 May; 21(3):164-73. doi:
10.1097/mjt.0b013e31824c3eb4. [PMID: 22713526] - Stephan Petersenn, Andrew J Farrall, Christophe De Block, Christophe Block, Shlomo Melmed, Jochen Schopohl, Philippe Caron, Ross Cuneo, David Kleinberg, Annamaria Colao, Matthieu Ruffin, Karina Hermosillo Reséndiz, Gareth Hughes, Ke Hu, Ariel Barkan. Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study.
Pituitary.
2014 Apr; 17(2):132-40. doi:
10.1007/s11102-013-0478-0. [PMID: 23529827] - Astrid Breitschaft, Ke Hu, Karina Hermosillo Reséndiz, Christelle Darstein, Georg Golor. Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study.
Diabetes research and clinical practice.
2014 Mar; 103(3):458-65. doi:
10.1016/j.diabres.2013.12.011. [PMID: 24461109] - R van der Pas, J H M van Esch, C de Bruin, A H J Danser, A M Pereira, P M Zelissen, R Netea-Maier, D M Sprij-Mooij, I M van den Berg-Garrelds, R H N van Schaik, S W J Lamberts, A H van den Meiracker, L J Hofland, R A Feelders. Cushing's disease and hypertension: in vivo and in vitro study of the role of the renin-angiotensin-aldosterone system and effects of medical therapy.
European journal of endocrinology.
2014 Feb; 170(2):181-91. doi:
10.1530/eje-13-0477. [PMID: 24165019] - S Petersenn, J Newell-Price, J W Findling, F Gu, M Maldonado, K Sen, L R Salgado, A Colao, B M K Biller. High variability in baseline urinary free cortisol values in patients with Cushing's disease.
Clinical endocrinology.
2014 Feb; 80(2):261-9. doi:
10.1111/cen.12259. [PMID: 23746264] - Pejman Cohan. Pasireotide and mifepristone: new options in the medical management of Cushing's disease.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
2014 Jan; 20(1):84-93. doi:
10.4158/ep13127.ra. [PMID: 24126229] - R van der Pas, C de Bruin, A M Pereira, J A Romijn, R T Netea-Maier, A R Hermus, P M Zelissen, F H de Jong, A J van der Lely, W W de Herder, S M Webb, S W J Lamberts, L J Hofland, R A Feelders. Cortisol diurnal rhythm and quality of life after successful medical treatment of Cushing's disease.
Pituitary.
2013 Dec; 16(4):536-44. doi:
10.1007/s11102-012-0452-2. [PMID: 23225121] - Tom J G Gevers, Joanna Inthout, Anna Caroli, Piero Ruggenenti, Marie C Hogan, Vicente E Torres, Frederik Nevens, Joost P H Drenth. Young women with polycystic liver disease respond best to somatostatin analogues: a pooled analysis of individual patient data.
Gastroenterology.
2013 Aug; 145(2):357-65.e1. doi:
10.1053/j.gastro.2013.04.055. [PMID: 23665274] - Lynnette K Nieman. Update in the medical therapy of Cushing's disease.
Current opinion in endocrinology, diabetes, and obesity.
2013 Aug; 20(4):330-4. doi:
10.1097/med.0b013e3283631809. [PMID: 23807605] - Edward M Wolin, Ke Hu, Gareth Hughes, Emmanuel Bouillaud, Vanessa Giannone, Karina Hermosillo Resendiz. Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I study.
Cancer chemotherapy and pharmacology.
2013 Aug; 72(2):387-95. doi:
10.1007/s00280-013-2202-1. [PMID: 23765178] - T-H Lin, K Hu, J Flarakos, M Sharr-McMahon, J B Mangold, H He, Y Wang. Assessment of the absorption, metabolism and excretion of [¹⁴C]pasireotide in healthy volunteers using accelerator mass spectrometry.
Cancer chemotherapy and pharmacology.
2013 Jul; 72(1):181-8. doi:
10.1007/s00280-013-2183-0. [PMID: 23680921] - Tatyana V Masyuk, Brynn N Radtke, Angela J Stroope, Jesús M Banales, Sergio A Gradilone, Bing Huang, Anatoliy I Masyuk, Marie C Hogan, Vicente E Torres, Nicholas F Larusso. Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases.
Hepatology (Baltimore, Md.).
2013 Jul; 58(1):409-21. doi:
10.1002/hep.26140. [PMID: 23172758] - Lin Lu, Lian Duan, Zimeng Jin, Zhaolin Lu, Feng Gu. Effective long-term treatment of Cushing's disease with pasireotide: a case report.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
2013 Jul; 19(4):e92-6. doi:
10.4158/ep12296.cr. [PMID: 23512383] - Pamela S Tietz Bogert, Bing Q Huang, Sergio A Gradilone, Tetyana V Masyuk, Gary L Moulder, Stephen C Ekker, Nicholas F Larusso. The zebrafish as a model to study polycystic liver disease.
Zebrafish.
2013 Jun; 10(2):211-7. doi:
10.1089/zeb.2012.0825. [PMID: 23668934] - Laurence Katznelson. Sustained improvements in plasma ACTH and clinical status in a patient with Nelson's syndrome treated with pasireotide LAR, a multireceptor somatostatin analog.
The Journal of clinical endocrinology and metabolism.
2013 May; 98(5):1803-7. doi:
10.1210/jc.2013-1497. [PMID: 23539733] - Kate McKeage. Pasireotide: a review of its use in Cushing's disease.
Drugs.
2013 May; 73(6):563-74. doi:
10.1007/s40265-013-0052-0. [PMID: 23605695] - Y Reznik, J Bertherat, F Borson-Chazot, T Brue, P Chanson, C Cortet-Rudelli, B Delemer, A Tabarin, S Bisot-Locard, B Vergès. Management of hyperglycaemia in Cushing's disease: experts' proposals on the use of pasireotide.
Diabetes & metabolism.
2013 Feb; 39(1):34-41. doi:
10.1016/j.diabet.2012.10.005. [PMID: 23228667] - Thomas J Quinn, Ziqiang Yuan, Asha Adem, Rula Geha, Chakravarthy Vrikshajanani, Wade Koba, Eugene Fine, David T Hughes, Herbert A Schmid, Steven K Libutti. Pasireotide (SOM230) is effective for the treatment of pancreatic neuroendocrine tumors (PNETs) in a multiple endocrine neoplasia type 1 (MEN1) conditional knockout mouse model.
Surgery.
2012 Dec; 152(6):1068-77. doi:
10.1016/j.surg.2012.08.021. [PMID: 23102680] - Stephan Petersenn, Nicole Unger, Ke Hu, Brigitte Weisshaar, Yilong Zhang, Emmanuel Bouillaud, Karina Hermosillo Reséndiz, Yanfeng Wang, Klaus Mann. Pasireotide (SOM230), a novel multireceptor-targeted somatostatin analogue, is well tolerated when administered as a continuous 7-day subcutaneous infusion in healthy male volunteers.
Journal of clinical pharmacology.
2012 Jul; 52(7):1017-27. doi:
10.1177/0091270011408727. [PMID: 21673137] - R van der Pas, C de Bruin, F W G Leebeek, M P M de Maat, D C Rijken, A M Pereira, J A Romijn, R T Netea-Maier, A R Hermus, P M J Zelissen, F H de Jong, A J van der Lely, W W de Herder, S W J Lamberts, L J Hofland, R A Feelders. The hypercoagulable state in Cushing's disease is associated with increased levels of procoagulant factors and impaired fibrinolysis, but is not reversible after short-term biochemical remission induced by medical therapy.
The Journal of clinical endocrinology and metabolism.
2012 Apr; 97(4):1303-10. doi:
10.1210/jc.2011-2753. [PMID: 22278425] - Yves Horsmans, Ke Hu, Matthieu Ruffin, Ying Wang, Dongweon Song, Emmanuel Bouillaud, Yanfeng Wang, Dago Mazur, Frans-Peter Botha, Douglas M Heuman. Effect of hepatic impairment on the pharmacokinetics of pasireotide (SOM230): results from a multicenter phase I study.
Journal of clinical pharmacology.
2012 Apr; 52(4):552-8. doi:
10.1177/0091270011400072. [PMID: 22282526] - Annamaria Colao, Stephan Petersenn, John Newell-Price, James W Findling, Feng Gu, Mario Maldonado, Ulrike Schoenherr, David Mills, Luiz Roberto Salgado, Beverly M K Biller. A 12-month phase 3 study of pasireotide in Cushing's disease.
The New England journal of medicine.
2012 Mar; 366(10):914-24. doi:
10.1056/nejmoa1105743. [PMID: 22397653] - Stephan Petersenn, Ke Hu, Mario Maldonado, Yilong Zhang, Janet Lasher, Emmanuel Bouillaud, Yanfeng Wang, Klaus Mann, Nicole Unger. Tolerability and dose proportional pharmacokinetics of pasireotide administered as a single dose or two divided doses in healthy male volunteers: a single-center, open-label, ascending-dose study.
Clinical therapeutics.
2012 Mar; 34(3):677-88. doi:
10.1016/j.clinthera.2012.01.015. [PMID: 22364824] - Herbert A Schmid, Josef Brueggen. Effects of somatostatin analogs on glucose homeostasis in rats.
The Journal of endocrinology.
2012 Jan; 212(1):49-60. doi:
10.1530/joe-11-0224. [PMID: 21987782] - Qiang Fu, Maaike Berbée, Wenze Wang, Marjan Boerma, Junru Wang, Herbert A Schmid, Martin Hauer-Jensen. Preclinical evaluation of Som230 as a radiation mitigator in a mouse model: postexposure time window and mechanisms of action.
Radiation research.
2011 Jun; 175(6):728-35. doi:
10.1667/rr2507.1. [PMID: 21529145] - V Preumont, L M Mermejo, P Damoiseaux, A Lacroix, D Maiter. Transient efficacy of octreotide and pasireotide (SOM230) treatment in GIP-dependent Cushing's syndrome.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
2011 Apr; 43(4):287-91. doi:
10.1055/s-0030-1270523. [PMID: 21264796] - Victor Castillo, Marily Theodoropoulou, Johanna Stalla, Maria Florencia Gallelli, Maria Fernanda Cabrera-Blatter, Mariana R Haedo, Marta Labeur, Herbert A Schmid, Günter K Stalla, Eduardo Arzt. Effect of SOM230 (pasireotide) on corticotropic cells: action in dogs with Cushing's disease.
Neuroendocrinology.
2011; 94(2):124-36. doi:
10.1159/000327429. [PMID: 21525729] - Sunil Manjila, Osmond C Wu, Fahd R Khan, Mehreen M Khan, Baha M Arafah, Warren R Selman. Pharmacological management of acromegaly: a current perspective.
Neurosurgical focus.
2010 Oct; 29(4):E14. doi:
10.3171/2010.7.focus10168. [PMID: 20887124] - Richard A Feelders, Christiaan de Bruin, Alberto M Pereira, Johannes A Romijn, Romana T Netea-Maier, Ad R Hermus, Pierre M Zelissen, Ramona van Heerebeek, Frank H de Jong, Aart-Jan van der Lely, Wouter W de Herder, Leo J Hofland, Steven W Lamberts. Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease.
The New England journal of medicine.
2010 May; 362(19):1846-8. doi:
10.1056/nejmc1000094. [PMID: 20463350] - Florian Pöll, Diana Lehmann, Susann Illing, Mihaela Ginj, Stefan Jacobs, Amelie Lupp, Ralf Stumm, Stefan Schulz. Pasireotide and octreotide stimulate distinct patterns of sst2A somatostatin receptor phosphorylation.
Molecular endocrinology (Baltimore, Md.).
2010 Feb; 24(2):436-46. doi:
10.1210/me.2009-0315. [PMID: 20051480] - Alberto M Pedroncelli. Medical treatment of Cushing's disease: somatostatin analogues and pasireotide.
Neuroendocrinology.
2010; 92 Suppl 1(?):120-4. doi:
10.1159/000314352. [PMID: 20829632] - M van Hoek, L J Hofland, Y B de Rijke, F H van Nederveen, R R de Krijger, P M van Koetsveld, S W J Lamberts, A J van der Lely, W W de Herder, R A Feelders. Effects of somatostatin analogs on a growth hormone-releasing hormone secreting bronchial carcinoid, in vivo and in vitro studies.
The Journal of clinical endocrinology and metabolism.
2009 Feb; 94(2):428-33. doi:
10.1210/jc.2008-1712. [PMID: 19017754] - Sarah Lesche, Diana Lehmann, Falko Nagel, Herbert A Schmid, Stefan Schulz. Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro.
The Journal of clinical endocrinology and metabolism.
2009 Feb; 94(2):654-61. doi:
10.1210/jc.2008-1919. [PMID: 19001514] - M Boscaro, W H Ludlam, B Atkinson, J E Glusman, S Petersenn, M Reincke, P Snyder, A Tabarin, B M K Biller, J Findling, S Melmed, C H Darby, K Hu, Y Wang, P U Freda, A B Grossman, L A Frohman, J Bertherat. Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial.
The Journal of clinical endocrinology and metabolism.
2009 Jan; 94(1):115-22. doi:
10.1210/jc.2008-1008. [PMID: 18957506] - Monica Fedele, Ivana De Martino, Rosario Pivonello, Andrea Ciarmiello, M Laura Del Basso De Caro, Rosa Visone, Dario Palmieri, Giovanna M Pierantoni, Claudio Arra, Herbert A Schmid, Leo Hofland, Gaetano Lombardi, Annamaria Colao, Alfredo Fusco. SOM230, a new somatostatin analogue, is highly effective in the therapy of growth hormone/prolactin-secreting pituitary adenomas.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2007 May; 13(9):2738-44. doi:
10.1158/1078-0432.ccr-06-2505. [PMID: 17473207] - A P Silva, P Schoeffter, G Weckbecker, C Bruns, H A Schmid. Regulation of CRH-induced secretion of ACTH and corticosterone by SOM230 in rats.
European journal of endocrinology.
2005 Sep; 153(3):R7-R10. doi:
10.1530/eje.1.01998. [PMID: 16131595] - Peiming Ma, Yanfeng Wang, Joost van der Hoek, Jerry Nedelman, Horst Schran, Ly-Le Tran, Steven W J Lamberts. Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly.
Clinical pharmacology and therapeutics.
2005 Jul; 78(1):69-80. doi:
10.1016/j.clpt.2005.04.003. [PMID: 16003295] - Antonio P Silva, Kerstin Bethmann, Friedrich Raulf, Herbert A Schmid. Regulation of ghrelin secretion by somatostatin analogs in rats.
European journal of endocrinology.
2005 Jun; 152(6):887-94. doi:
10.1530/eje.1.01914. [PMID: 15941929] - H A Schmid, A P Silva. Short- and long-term effects of octreotide and SOM230 on GH, IGF-I, ACTH, corticosterone and ghrelin in rats.
Journal of endocrinological investigation.
2005; 28(11 Suppl International):28-35. doi:
. [PMID: 16625842] - Alberto M Pereira, Nienke R Biermasz, Ferdinand Roelfsema, Johannes A Romijn. Pharmacologic therapies for acromegaly: a review of their effects on glucose metabolism and insulin resistance.
Treatments in endocrinology.
2005; 4(1):43-53. doi:
10.2165/00024677-200504010-00005. [PMID: 15649100] - Gisbert Weckbecker, Ulrich Briner, Ian Lewis, Christian Bruns. SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs.
Endocrinology.
2002 Oct; 143(10):4123-30. doi:
10.1210/en.2002-220219. [PMID: 12239124] - C Bruns, I Lewis, U Briner, G Meno-Tetang, G Weckbecker. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile.
European journal of endocrinology.
2002 May; 146(5):707-16. doi:
10.1530/eje.0.1460707. [PMID: 11980628]